In 2003, 69% of the U.S. cases of IPD prevented by PCV use have been estimated to result from the indirect effects of vaccination [3]. Not all changes in pneumococcal serotype prevalence, however, are attributable to vaccine, and factors such as secular find protocol trends and changes in surveillance programs need to be taken into account. Measuring NP carriage of bacteria is challenging because the nasopharynx can be a difficult site

to sample consistently, multiple bacterial species and serotypes reside in the nasopharnyx at any given time and in varying abundance. As presented by Dr. Catherine Satzke, current standards for NP sampling were published in 2003 and established the use of NP swabs as the preferred method of sampling [4]. Forskolin price While generally still relevant, the increasing use of non-culture methods of isolation has led to some revision of the type of swabs used. NP sampling methods have been the subject of a separate WHO consultation and these proceedings will be published

in 2013. The simultaneous NP carriage of multiple serotypes of pneumococcus presents a particular challenge in the standardization of NP sampling methods. New, more sensitive methods of serotyping are emerging that will aid in assessing the true rate of multiple carriage and help address questions that until now have not been possible to answer. Responding to the lack of a standard for the epidemiological sampling and statistical estimation of vaccine efficacy against pneumococcal colonization, VE-col, PneumoCarr collaborators undertook simulation and modeling studies for

the following three purposes: (1) to develop statistical methods for the estimation of VE-col in phase III and IV studies, (2) to improve the interpretation of VE-col estimates for better comparability across different studies, and (3) to specify the minimum requirements for the use of cross-sectional data for VE-col estimation. Dr. Kari Auranen presented the main findings from these efforts at the consultation (See Ref. [19]: Section VI). Vaccine efficacy against acquisition (VE-acq) and vaccine efficacy against transmission potential (VE-tp) are the two parameters that are most relevant to the direct and indirect protection due to vaccination, and respectively [5] and [6]. Unlike disease endpoints which can be measured as incident cases, colonization endpoints are usually measured based on prevalence data from cross-sectional studies. VE-tp can be estimated from prevalence data under weak assumptions, the most important of which is that the study population is in a stationary phase where overall pneumococcal carriage prevalence and serotype distribution are not changing. If it is assumed that the vaccine does not impact duration of colonization – as some studies indicate – then VE-tp approximates VE-acq, and thus this parameter of primary interest (VE-acq) is also measurable from cross-sectional data.